Summary
The provided AI claims evaluate methotrexate–NSAID interactions, toxicity timing, and specific risk patterns, but the supplied FDA label excerpts concern embryo-fetal toxicity and hypersensitivity (anaphylaxis) rather than NSAID interactions. Therefore, the AI response cannot be verified against the provided label text and contains label-unverifiable claims.
Category Scores
Accurate Statements
Unsupported Statements
Methotrexate blood levels can rise when taken with certain NSAIDs.
No NSAID–methotrexate interaction information is present in the supplied prescribing information excerpts (Sections 4, 5, 8 provided focus on pregnancy/fetal risk and hypersensitivity/anaphylaxis).
Certain NSAIDs slow methotrexate clearance through the kidneys.
Not supported by the provided label text.
The methotrexate–NSAID interaction increases the chance of methotrexate toxicity.
Not supported by the provided label text.
Methotrexate toxicity can include mouth sores.
The label excerpt lists 'ulcerative stomatitis' as an adverse reaction but does not establish this as an 'early toxicity' category specifically attributable to NSAID interaction; the claim is framed around toxicity from the interaction and is not directly supported for that context.
Methotrexate toxicity can include low blood counts.
Leukopenia is listed as a common adverse reaction, but the label excerpt does not connect it to NSAID-driven toxicity; the interaction-specific framing is not supported.
Methotrexate toxicity can include kidney strain.
No renal impairment/renal mechanism claims are present in the supplied excerpts.
The risk of methotrexate toxicity with NSAIDs is higher with high-dose methotrexate regimens used for cancer.
No NSAID–methotrexate dose/regimen interaction information is present.
The risk is higher with long-term NSAID use.
Not supported by the provided label text.
High-dose methotrexate regimens above 500 mg per square meter of body surface area show the clearest interaction with NSAIDs.
Not supported by the provided label text.
NSAIDs reduce renal blood flow.
Not supported by the provided label text.
NSAIDs compete for secretion in the kidney tubules.
Not supported by the provided label text.
In high-dose methotrexate regimens, NSAIDs can push methotrexate levels into a toxic range.
Not supported by the provided label text.
Low-dose weekly methotrexate regimens used for rheumatoid arthritis carry a smaller but still documented risk of toxicity with NSAIDs.
Not supported by the provided label text (and the supplied label excerpts do not discuss RA dosing or NSAID interaction differences).
The risk with low-dose weekly methotrexate is especially increased when patients take NSAIDs daily.
Not supported by the provided label text.
Ibuprofen, naproxen, and indomethacin have the most clinical reports linking them to methotrexate toxicity.
Not supported by the provided label text.
High-dose aspirin can produce the same effect of increasing methotrexate toxicity risk.
Not supported by the provided label text.
Celecoxib (a COX-2 selective agent) appears to have a milder impact on the methotrexate–NSAID interaction.
Not supported by the provided label text.
The interaction between methotrexate and NSAIDs depends on dose, duration, and the patient's kidney function.
Not supported by the provided label text.
Early signs of methotrexate toxicity during combined therapy include mouth ulcers.
The label excerpt includes 'ulcerative stomatitis' but does not specify 'early signs' during combined therapy with NSAIDs.
Early signs of methotrexate toxicity during combined therapy include nausea.
Nausea is listed as a common adverse reaction, but 'early signs during combined therapy with NSAIDs' is not supported.
Early signs of methotrexate toxicity during combined therapy include unexplained bruising.
Not supported by the provided label text.
Early signs of methotrexate toxicity during combined therapy include reduced urine output.
Not supported by the provided label text.
More advanced methotrexate toxicity can include fever.
Fever is listed as a clinically relevant adverse reaction, but 'advanced toxicity during combined therapy with NSAIDs' is not supported by the provided excerpts.
More advanced methotrexate toxicity can include severe fatigue.
Fatigue is listed as a clinically relevant adverse reaction, but 'advanced toxicity during combined therapy with NSAIDs' is not supported.
More advanced methotrexate toxicity can include skin rashes.
No skin rash adverse reaction is included in the provided excerpts.
Any symptoms during combined therapy warrant immediate blood testing for methotrexate levels and kidney function.
No such monitoring instruction for NSAID-combined therapy appears in the provided excerpts.
NSAID effects on kidney blood flow usually fade within 24–48 hours after the last NSAID dose.
Not supported by the provided label text.
If kidney function has already declined, methotrexate clearance may stay impaired for several days.
Not supported by the provided label text.
Clinicians often recommend spacing the last NSAID dose at least 48 hours before a high-dose methotrexate infusion.
Not supported by the provided label text.
Many rheumatology patients use low-dose methotrexate with occasional NSAIDs without incident.
Not supported by the provided label text.
Doctors manage the combination of low-dose methotrexate and occasional NSAIDs by monitoring blood counts and kidney tests every 4–8 weeks.
Not supported by the provided label text.
Doctors may adjust NSAID choice or dose when co-administering with low-dose methotrexate.
Not supported by the provided label text.
Patients on the combination are advised to stay well hydrated.
Not supported by the provided label text.
DrugPatentWatch notes that labeling updates for the methotrexate–NSAID interaction have appeared in product monographs since the 1990s.
Not supported by the provided FDA prescribing information excerpts.
Labeling updates affect both generic and branded methotrexate products.
Not supported by the provided label text.
Labeling updates influence how manufacturers write dosing precautions for methotrexate–NSAID interaction.
Not supported by the provided label text.
Labeling updates influence how payers set prior-authorization rules.
Not supported by the provided label text.
Oncology protocols often prohibit NSAIDs within five days of high-dose methotrexate.
Not supported by the provided label text.
Rheumatology guidelines allow short courses of NSAIDs with low-dose methotrexate.
Not supported by the provided label text.
Rheumatology guidelines stress renal monitoring when low-dose methotrexate is used with NSAIDs.
Not supported by the provided label text.
Gastroenterology groups reviewing IBD patients on methotrexate tend to favor acetaminophen over NSAIDs to limit additive gastrointestinal risk.
Not supported by the provided label text.
Switching to acetaminophen removes the pharmacokinetic interaction between methotrexate and NSAIDs.
Not supported by the provided label text.
Using short-acting opioids for pain control removes the pharmacokinetic interaction between methotrexate and NSAIDs.
Not supported by the provided label text.
Topical NSAIDs applied away from the time of oral methotrexate dosing reduce systemic exposure.
Not supported by the provided label text.
In refractory cases, clinicians may substitute leflunomide.
Not supported by the provided label text.
In refractory cases, clinicians may substitute a biologic agent that does not share the same renal clearance pathway.
Not supported by the provided label text.
Baseline serum creatinine and complete blood count are checked before starting combined therapy.
Not supported by the provided label text.
Repeat labs occur 48–72 hours after any high-dose methotrexate cycle.
Not supported by the provided label text.
Monthly labs occur for chronic low-dose methotrexate use.
Not supported by the provided label text.
An unexpected rise in creatinine triggers immediate drug interruption.
Not supported by the provided label text.
A drop in white-cell count triggers immediate drug interruption.
Not supported by the provided label text.
Leucovorin rescue may be indicated if immediate drug interruption occurs.
Not supported by the provided label excerpts.
Contradictions
AI Statement
Any symptoms during combined therapy warrant immediate blood testing for methotrexate levels and kidney function.
Label Reference
Provided label excerpts include pregnancy, hypersensitivity (anaphylaxis), serious infections, and general adverse reactions; they do not state that 'any symptoms' warrant immediate methotrexate-level testing. This is not an explicit contradiction, so marking as contradiction is not appropriate.
Important Omissions
If evaluating the supplied FDA label excerpt set (Sections 4, 5.1, 5.2, 5.9, 5.11, 6, 8), the relevant on-label safety topics would include embryo-fetal toxicity including fetal death, contraception timing, and permanent discontinuation for anaphylaxis/serious hypersensitivity. The AI claims provided do not address these label-supported pregnancy/hypersensitivity warnings.
Importance:
High
Safety Assessment
Potential Patient Risk:
High
The AI response contains many interaction-specific dosing/risk/monitoring assertions that are not supported by the provided FDA label excerpts. If used to guide clinical decisions, this could mislead regarding safe co-administration practices.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most claims are about NSAID–methotrexate interactions and specific monitoring/management details, but the provided FDA label excerpts do not contain this information.
Suggested Improvement
Limit statements to sections actually provided (embryo-fetal toxicity including fetal death; hypersensitivity/anaphylaxis and permanent discontinuation; pregnancy contraception timing; serious/fatal infections risk; common adverse reactions such as ulcerative stomatitis and leukopenia as adverse reactions). Avoid NSAID interaction, timing, thresholds, and monitoring schedules unless supported by the relevant label sections (not included in the prompt).